Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,501–1,600 of 3,704
Jordan, G., Young, S., & Alemán, J. O. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.006 · Cited by 12
Game-changing obesity drugs go mainstream: what scientists are learning
Lenharo, M. (2023) · Nature · doi:10.1038/d41586-023-01712-8 · Cited by 11
A phenotypic approach to obesity treatment
Zandvakili, I., Pulaski, M., & Pickett‐Blakely, O. (2023) · Nutrition in Clinical Practice · doi:10.1002/ncp.11013 · Cited by 8
Rangraze, I. R., Patoulias, D., Karakasis, P., El‐Tanani, M., & Rizzo, M. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2408753 · Cited by 8
“Similar results were reported in relevant trials enrolling individuals with over-weight or obesity without baseline T2D, demonstrating an achieved weight loss up to 20.9% with tirzepatide compared to placebo, if titrated up to the maximum dose of 15 mg once weekly [7].”
InfluentialKushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities · doi:10.3390/obesities5020029 · Cited by 5
“The size Pla-cebo-adjusted discontinuation due to diarrhea was ≤ 2% in all publications that reported the AE [12,36,52,70,94,103].”
InfluentialComprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide
Sattar, N., Linetzky, B., Ruotolo, G., Verma, S., Sourij, H., Wang, H., Vanderman, K., Wilson, J. M., Griffin, R. M., Stefanski, A., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.04.044 · Cited by 5
Self-citationA Survey of Obesity Education and Training in United States Pharmacy Schools
Phillips, E. J., Traina, A. N., & Smolarz, B. G. (2023) · American Journal of Pharmaceutical Education · doi:10.1016/j.ajpe.2023.100109 · Cited by 10
“22,23 Several factors in successfully managing obesity and improving patient outcomes include effective healthcare treatment options, coverage for AOMs and other treatments, and societal and healthcare policies.”
BackgroundManagement of Medication-Induced Weight Gain
Barenbaum, S. R., Kumar, R. B., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.006 · Cited by 6
Self-citationBallesteros-Pomar, M. D., Rodríguez-Urgellés, E., Sastre-Belío, M., Martín‐Lorenzo, A., Schnecke, V., Segú, L., Brosa, M., & Vilarrasa, N. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03094-3 · Cited by 12
Ferrari, R., Gowdak, L. H. W., Padilla, F., Quek, D. K., Ray, S., Rosano, G. M. C., Indolfi, C., & Filardi, P. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041161 · Cited by 11
“New classes of medications have been developed that safely promote weight loss and, in turn, reduce the incidence of cardiovascular events, such as cardiovascular death, myocardial infarction, or stroke [15–17].”
Obesity and its treatment: Toward new approaches
Segrestin, B., & Cherifi, B. G. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.101712 · Cited by 7
The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid Management
Suter, B., Rhodes, A. L., Bigeh, A., Frommeyer, T. C., & Mehta, L. S. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00761-0 · Cited by 8
“The population in SELECT was different that STEP-1 and SUMOUNT 1, with 90.1% of patients on lipid-lowering therapy and a much lower baseline LDL-C of 78 mg/dL compared to 111 mg/dL and 110 mg/dL in STEP-1 and SURMOUNT 1 respectively [33, 35, 48].”
InfluentialShen, J., Wang, M., Pang, G., Zhang, Y., Zhang, J., Shi, Y., Liu, J., & Zhan, C. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00528.2024 · Cited by 7
Obesity Management in South Asian Context
Das, S., Chappalagavi, A. S., Choudhury, A. K., Meher, D., Sahoo, D., Sahu, S. K., & Gupta, S. (2025) · Apollo Medicine · doi:10.1177/09760016251325966 · Cited by 5
Euglycemic Ketoacidosis in a Non-diabetic Patient After Tirzepatide Use: A Cautionary Tale
Singh, R. (2025) · Cureus · doi:10.7759/cureus.83187 · Cited by 7
“Tirzepatide (Mounjaro™), a once-weekly injectable dual GLP-1/GIP receptor agonist, has shown significant promise in clinical trials such as SURMOUNT-1, demonstrating an average weight reduction of up to 22.5% at higher doses in non-diabetic patients [4].”
InfluentialKim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
Ono, R., & Falcão, L. M. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.02.007 · Cited by 11
Napoli, M. D., Rouhi, A. D., Baimas‐George, M. R., Dumon, K. R., Castle, R., Kennealey, P. T., Nydam, T. L., & Choudhury, R. A. (2025) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116475 · Cited by 6
Pokushalov, E., Garcia, C., Ponomarenko, A., Самойлова, Ю. Г., Smith, J. W., Johnson, M., Алексеевна, П. И., Shrainer, E., Kudlay, D. A., Romanova, A., et al. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.06.035 · Cited by 7
Zhang, Z., Li, A., Zheng, J., Liang, Y., Ma, L., & Su, L. (2025) · Endocrine Connections · doi:10.1530/ec-25-0205 · Cited by 8
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside
O’Donnell, C., King, A., Vial, G., O'Neill, E., Crilly, S., Dodd, J. D., Murphy, D. J., Belaïdi, E., Pépin, J., Arnaud, C., et al. (2025) · Journal of Sleep Research · doi:10.1111/jsr.70152 · Cited by 6
Alqatari, S. G., Alwaheed, A., Hasan, M. A., Argan, R. A., Alabdullah, M. M., & Shubbar, M. D. A. (2025) · Medicina · doi:10.3390/medicina61071292 · Cited by 11
“Sleeve Gastrectomy GLP-1 RA ( Total Weight Loss% Up to ~31% [59,60] Up to ~22% [61,62] ~15% [19] ~21% [33] ~24.2% (weight loss continued without plateauing at the end of the trial) [36] Impact on Comorbidities High remission rate of T2DM, HTN, OSA [63] High remission rate of T2DM, HTN, OSA [63]…”
InfluentialEvolution of multidisciplinary obesity treatments: past, present, and future role of nutrition
Heymsfield, S. B., Atherton, P. J., Christensen, S. M., Tewksbury, C. M., Velazquez, A., Walter, J., & Blaak, E. E. (2025) · Obesity · doi:10.1002/oby.24340 · Cited by 7
“[51 – 54].”
InfluentialCase Report: Rhabdomyolysis following initiation of tirzepatide
Bodanowitz, J. M., Mattes, I., Loebermann, M., & Fritzsche, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1660785 · Cited by 5
Weight management treatment in obesity
Rubio, M. Á., & Carreiro, S. M. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107152 · Cited by 7
Koenig, Z. A., Rashid, S., Hobbs, G. R., & Uygur, H. S. (2025) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000012405 · Cited by 12
The evolving burden of obesity in the US: a novel population-level system dynamics approach
McEwan, P. C., Faurby, M. D., Lübker, C., Padgett, T., & Toliver, J. C. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2554518 · Cited by 9
“Contemporary GLP-1 RAs have been associated with mean weight loss of between 15% 15 and 21% 16 in people living with obesity.”
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
“126 Setmelanotide Setmelanotide is a daily subcutaneous injection which acts as a melanocortin-4 (MC4) receptor agonist, and was approved by the FDA in 2020 in patients with obesity arising from genetically confirmed Bardet-Biedl syndrome (BBS), POMC, PCSK1, or LEPR deficiency.”
Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies
Witaszek, T., Biesiada, A. M., Iskra-Trifunović, J., Babicki, M., Mastalerz–Migas, A., & Kłoda, K. (2025) · Biomedicines · doi:10.3390/biomedicines13102362 · Cited by 8
Cerchi, E., Santo, P. A. D. E., de Oliveira, M. C., Janovsky, C. C. P. S., & Halpern, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01920-4 · Cited by 9
Hoog, M. M., Vallarino, C. R., Maldonado, J. M., Grabner, M., Teng, C., Terrell, K. A., & Richard, E. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01794-9 · Cited by 11
Jacobson, S., Margolese, N., & Margolese, H. C. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251386626 · Cited by 11
Silverii, G. A., Monami, M., Rotella, F., Luca, M. D., Viozzi, T., Barazzoni, R., Buscemi, S., Busetto, L., Sbraccia, P., & Mannucci, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70202 · Cited by 6
“…adverse events were heterogeneous across trials: all trials except two 21,23 used the Medical Dictionary for Regulatory Activities to define adverse events, with 7 and 10 studies also using questionnaire scores as regards to depression 21,25,27 – 29,31,33,37,45,46 and suicidality, 25,29, 31,”
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Wiśniewski, K., Choromańska, B., Maciejczyk, M., Dadan, J., & Myśliwiec, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217648 · Cited by 5
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 9
“Clinically, this translates to superior glycemic control and weight loss compared to selective GLP-1R agonists [181,188].”
GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis
Alves, K. M., da Silva, M. T., Kramer, C. K., & Viana, L. V. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf150 · Cited by 14
Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
Pomenti, S. F., Gerber, A. R., Katzka, D. A., Camilleri, M., & Hur, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70450 · Cited by 9
Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70263 · Cited by 7
“7,8,11,12 While the reason for this difference in weight loss is unclear, there is a strong unmet need for medications that produce greater weight loss in people with T2D.”
Self-citationMetabolic and appetitive regulation of adipocyte mass during treatment of obesity
Purnell, J. Q., & le Roux, C. W. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70045 · Cited by 11
“The amount of time that rodents need to move from one state of homeostasis (pre-intervention) to a new state of homeostasis (post-intervention) appears to be between 20 and 30 days, whereas the same process takes up to 12–18 months in humans [72, 73].”
Tirzepatide-Induced Liver Injury: A Rare Complication
Spaeth, L. D., Jordan, K. M., Barlow, M., & Cottrell, D. A. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.11.009 · Cited by 5
Hong, A. T., Lin, F., Baxter, S. L., & Weinreb, R. N. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.12.003 · Cited by 8
Obesity and emerging intervention strategies: Mechanistic insights and novel drug targets
Feng, X., Li, S., Li, J., & Su, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003919 · Cited by 7
“[157] In a phase III trial, body weight reduction of 12.3% to 19.7% were observed across different dose groups, and a concurrent reduction in the risk of T2D progressing.”
InfluentialThe male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems
Antonič, K. G., & Zitzmann, M. (2025) · The Aging Male · doi:10.1080/13685538.2025.2601423 · Cited by 7
“Similar observations have been reported with tirzepatide in the SURMOUNT-1 trial, where dual GLP-1/GIP receptor agonism resulted in profound fat mass loss accompanied by measurable declines in lean tissue [141].”
Beyond metabolism: sexual dysfunction and weight-loss drugs
Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Mendoza-Godoy, J. J., Urteaga, L. A. C., Paz‐Ibarra, J., & Arroyo, J. (2025) · Sexual Medicine Reviews · doi:10.1093/sxmrev/qeaf074 · Cited by 10
The evolving role of metabolic and bariatric surgery in contemporary clinical practice
Panichella, G., Gentile, F., Nannipieri, M., & Emdin, M. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf787 · Cited by 6
Potential Role of Imaging in the Evaluation of Adiposity and Approval of Anti-Obesity Drugs
Kim, S. Y., Won, S. E., Park, H. J., Woo, C.-Y., Kim, D. W., Suh, C. H., & Kim, K. W. (2026) · Korean Journal of Radiology · doi:10.3348/kjr.2025.0937 · Cited by 6
“In contrast, the tirzepatide group experienced a markedly greater 33.9% reduction in total fat mass, accompanied by a substantial decrease in the fat-to-lean mass ratio, from 0.93 to 0.70 [64].”
InfluentialPharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
“Notably, a high proportion of participants achieved clinically meaningful thresholds of weight loss: 89% of those on tirzepatide 15 mg lost at least 5% of BW, 86% lost ≥ 10%, and over 50% achieved ≥ 20% weight reduction [ 72].”
InfluentialAlavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Almandoz, J. P., Pickett‐Blakely, O., Tewksbury, C. M., Stefański, A., Gonsahn-Bollie, S., Dimitriadis, G. K., Murro, A. L., Cao, D., Meng, Q., & Neff, L. M. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100248 · Cited by 10
“The phase 3 randomized, placebo-controlled, SURMOUNT-1-4 trials [4 – 7] were conducted in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines.”
InfluentialSelf-citationA treat‐to‐target approach for obesity management: A post hoc analysis of the SURMOUNT ‐5 trial
le Roux, C. W., Busetto, L., Aronne, L. J., Horn, D. B., Dimitriadis, G. K., Falcón, B. L., García‐Pérez, L., Valderas, E. G., Gibble, T. H., Şenyücel, Ç., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70531 · Cited by 5
“45,46 Importantly, the measures used are predictive of long-term outcomes 35,36,47 – 48 and are already commonly assessed in clinical practice.”
Self-citationOcular Outcomes with Tirzepatide versus Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes
Hong, A. T., Lin, F., Keenan, J. D., & Stewart, J. M. (2026) · Ophthalmology Retina · doi:10.1016/j.oret.2026.02.002 · Cited by 9
Wali, A. F., Rangraze, I. R., Khan, S. S., Mufti, U., El‐Tanani, M., & Rizzo, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736380 · Cited by 7
Who Wins the Battle Against Obesity? A Network Meta-Analysis Comparing Tirzepatide and Semaglutide
Bernardi, J. C., Cavalcante, D. V. S., Huntermann, R., Molinari, M. E., Zanon, L. Z., Khater, J., Gomez, V. A., & Fischer‐Bacca, C. O. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70192 · Cited by 5
“The SURMOUNT trials showed significant reductions in weight and improvements in glycemic control with a favorable safety and tolerability profile [13–16].”
InfluentialPolymeri, A., Feres, M., Giannobile, W. V., & Loos, B. G. (2026) · Journal of Periodontology · doi:10.1002/jper.70092 · Cited by 14
Ahmed, M., Hassan, M., Tahir, M., Hussain, M., Islam, F., Khan, G. T., Ahsan, M. N., Shafiq, S. S., Ibrahim, A., Uddin, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70667 · Cited by 9
Edvardsson, C. E., Zhang, X., Emous, T. A., Adermark, L., Witley, S., Ericson, M., Schmidt, H. D., & Jerlhag, E. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106219 · Cited by 7
“17,28–31 31 Interestingly, tirzepatide favours GIPR over GLP-1R binding while preserving distinct GLP-1R signalling properties, 32 potentially relevant since GIPR seems to influence addiction processes independently and in combination with GLP-1R.”
Belančić, A., Fajkić, A., Şener, Y. Z., Jelaković, A., Alić, L., Gkrinia, E. M. M., Verbanac, D., & Jelaković, B. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70159 · Cited by 7
“Glucagon-like peptide-1 (GLP-1) receptor agonists, including liraglutide and semaglutide, as well as the dual GLP-1/ GIP receptor agonist tirzepatide, have revolutionised obesity pharmacotherapy with concurrent BP-lowering effects [9–11].”
InfluentialAl-Awadi, A. A., Alroudhan, D., Alsaeed, D., Almarshad, B. W., Alshehabi, D. H., Al‐Lahou, B., Mashankar, A., Al‐Ozairi, E., & Gray, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116911 · Cited by 16
“15 While these therapies are highly effective, strategies to preserve muscle mass and function, particularly in older adults, are essential to mitigate the risk of sarcopenia and support overall metabolic and functional health due to the wide-ranging importance of skeletal muscle for health.”
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Rutigliani, G., Cross, T.-W., de Jong, E., Glover, E. S., Mendoza, I. D., Adisa, M., Tomoo, K., Zhou, X., & Mattes, R. D. (2026) · Obesity Reviews · doi:10.1111/obr.70148 · Cited by 5
From obesity to cardiovascular disease: pathological basis and clinical implications
Nardin, M., Mehran, R., Oliva, A., Kedhi, E., Galasso, G., Nardin, S., Savonitto, S., Condorelli, G., & Luca, G. D. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.04.041 · Cited by 7
Sclafani, M., Spartera, M., Esmati, Y., Baynham-Williams, O., Khan, I., Brigoli, M., Krasopoulos, C., Ormerod, J., Tang, P., Rider, O. J., et al. (2026) · JAMA · doi:10.1001/jama.2026.5787 · Cited by 12
Pharmacologic Management of Obesity after Liver Transplantation: A Critical Review.
Zahrawi, F. M., Fathma, S., Mehal, W. Z., & Banini, B. A. (2023) · PubMed · Cited by 9
Diagnostic et évaluation de l’hépatopathie stéatosique métabolique
Canivet, C. M., & Faure, S. (2023) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2023.10.438 · Cited by 5
Chen, S.-Y., Telfser, A. J., Olzomer, E. M., Vancuylenberg, C. S., Zhou, M., Beretta, M., Li, C., Alexopoulos, S. J., Turner, N. A., Byrne, F. L., et al. (2024) · Clinical Science · doi:10.1042/cs20231016 · Cited by 9
Lin, D., Xiao, H., Yang, K., Li, J., Ye, S., Liu, Y., Jing, S., Yang, L., Yang, Y., Huang, L., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03394-z · Cited by 6
Trends in cardiovascular health among US adults by glycemic status based on Life's Essential 8
Sun, S., Yao, M.-D., Liu, X., Li, J., Chen, X.-L., Huang, W.-W., Ni, S.-H., Ou-Yang, X.-L., Yang, Z.-Q., Li, Y., et al. (2024) · Preventive Medicine · doi:10.1016/j.ypmed.2024.108042 · Cited by 4
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
“…liraglutide [28, 30–36] and lixisena-tide [37], or long duration (once-weekly administration) including extended-released exenatide [38–43], albiglutide [44–47], dulaglutide [28, 48–50], oral or injectable sema-glutide [28, 51–55], and tirzepatide [56–60] have also been approved for clinical use.”
Talay, L., Vickers, M., & Wu, S. (2024) · Telemedicine Reports · doi:10.1089/tmr.2024.0023 · Cited by 5
Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss
Gross, K., & Brinkmann, C. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1449653 · Cited by 7
Cross, L. V. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae273 · Cited by 8
Clinician’s Guide for Pediatric Anti-obesity Medications
Dutton, W. P., Paddu, N. U., Braddock, A. S., & Sweeney, B. R. (2024) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2024.07.006 · Cited by 5
Development of the novel amylin and calcitonin receptor activators by peptide mutagenesis
Lee, S. M. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110191 · Cited by 5
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss
Sforzo, G. A., Gordon, N. F., Peeke, P. M., & Moore, M. A. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241302273 · Cited by 8
“6 Additionally, other reported bene fi ts include pancreatic beta cell proliferation, lowering of blood pressure and cholesterol, improved cardiac function, and lower risk of cardiac events.”
Dobbie, L. J., Birney, S., Breen, C., Bryant, S., Clare, K., Ciudin, A., Felsenreich, D. M., Halford, J. C. G., Heneghan, H., Lorenzo, N. D., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000002171 · Cited by 9
Koullias, E., Papavdi, M., Koskinas, J. S., Deutsch, M. J., & Thanopoulou, A. C. (2025) · Cureus · doi:10.7759/cureus.76716 · Cited by 13
A perspective on intermittent fasting and cardiovascular risk in the era of obesity pharmacotherapy
Eliopoulos, A. G., Gkouskou, K. K., Tsioufis, K. P., & Sanoudou, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1524125 · Cited by 8
Obesity Management for Patients with Coronary Artery Disease and Heart Failure
Syed, A. A., Adam, S., Miller, C., & Alkhaffaf, B. H. (2025) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.12.006 · Cited by 6
Kamrul-Hasan, A. B. M., Pappachan, J. M., Dutta, D., Nagendra, L., Kuchay, M. S., & Kapoor, N. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i4.101731 · Cited by 8
Low Energy Diets for Obesity and CKD (SLOW-CKD Randomized Feasibility Study)
Conley, M. M., Mayr, H. L., Hepburn, K. S., Holland, J. J., Mudge, D. W., Tonges, T. J., Modderman, R. S., Gerzina, S. A., Johnson, D. W., Viecelli, A. K., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.04.021 · Cited by 7
“13,14 14-16 However, these medications have side effects, recurring high costs, 17 and global shortages are impacting continuity of care.”
Xu, B., Gaynor-Sodeifi, K., & Kundel, V. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03312-6 · Cited by 6
The Role of Exercise in the Contemporary Era of Obesity Management Medications
Jakicic, J. M., & Rogers, R. J. (2025) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000001272 · Cited by 6
Bang, M., Shin, S., Kim, J., Kang, M., Lee, D., Kim, J., Kim, C., Son, J., Choi, S., Jeon, S., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091396 · Cited by 11
The treatment of diabetes in advanced liver disease: change of a paradigm
Petroni, M. L., Brodosi, L., & Marchesini, G. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100772 · Cited by 5
“Bene fi cial effects might also be achieved by high dose semaglutide and tirzepatide, causing 15% mean weight reduction [31 32], provided that the negative effects of weight loss-associated sarcopenia are adequately corrected [33].”
BackgroundHuman brown adipose tissue function: insights from current in vivo techniques
Kwok, T. C., & Stimson, R. H. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0017 · Cited by 13
Valdés, S., Vilarrasa, N., Rubio, M. Á., de Hollanda, A., & Area of Obesity of the Spanish Society of Endocrinology and Nutrition (Obesity SEEN) (2023) · Obesity Surgery · doi:10.1007/s11695-023-06665-5 · Cited by 5
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children
Dallatana, A., Cremonesi, L., Trombetta, M., Fracasso, G., Nocini, R., Giacomello, L., & Innamorati, G. (2023) · Biomedicines · doi:10.3390/biomedicines11061576 · Cited by 7
“GIPR-GLP1R GIP, GLP1 Incretinic effect stimulation Phase III clinical trials (Tirzepatide) [90]”
BackgroundMicheroli, R., Bhatia, S., Vallejo‐Yagüe, E., et al. (2023) · The Journal of Rheumatology · doi:10.3899/jrheum.2023-0137 · Cited by 5
Obesity in Heart Failure with Reduced Ejection Fraction
Amdahl, M. B., Sundaram, V., & Reddy, Y. N. V. (2023) · Cardiology Clinics · doi:10.1016/j.ccl.2023.06.010 · Cited by 8
Four key questions on the new wave of anti-obesity drugs
Prillaman, M. (2023) · Nature · doi:10.1038/d41586-023-02445-4 · Cited by 7
Obesity management for the hepatologist—What to do, how to do it and why?
Watt, K. D. S., Paul, S., Khan, M. Q., Siddiqui, M. S., Lam, J., Diwan, T. S., & Camilleri, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000598 · Cited by 5
Management of Type 2 Diabetes Mellitus
Kawa, L. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002478 · Cited by 7
Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes
Patoulias, D., Popovic, D. S., Koufakis, T., Stavropoulos, K., & Doumas, M. N. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.12.022 · Cited by 5
Gastrointestinal hormones: History, biology, and measurement
Rehfeld, J. F., & Goetze, J. P. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.11.004 · Cited by 6
Hope, D. C. D., Ansari, S., Choudhury, S., Αλεξιάδου, Κ., Tabbakh, Y., Ilesanmi, I., Lazarus, K., Davies, I., Jimenez‐Pacheco, L., Yang, W. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15448 · Cited by 6
“4,5 8 This strategy leverages GLP-1R-mediated reduction in food intake in addition to GCGR-mediated enhanced energy expenditure and hepatic lipid catabolism.”
Integrating Pharmacotherapy and Psychotherapy for Weight Loss
Sanzone, M., & Sammons, M. T. (2023) · Journal of Health Service Psychology · doi:10.1007/s42843-023-00095-8 · Cited by 5
“Clinical trials indicate significant weight loss of approximately 35 to 52 pounds after 72 weeks of continuous use (Jastreboff et al., 2022).”
EndoBridge 2023: highlights and pearls
Yıldız, B. O., Boguszewski, C. L., Boguszewski, M. C. D. S., Busetto, L., Celik, O., Fuleihan, G. E., Goulis, D. G., Hammer, G. D., Haymart, M. R., Kaltsas, G., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00549-8 · Cited by 5
“Tirzepatide (Mounjaro), an injectable dual gastric inhibitory peptide (GIP) and GLP-1 receptor agonist, has demonstrated an even greater mean weight loss of over 20% at the highest dose of weekly tirzepatide 15 mg in the SUR-MOUNT-1 trial [44].”
Rethinking the label anti-obesity medication
Flint, S. W. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00071-8 · Cited by 6
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.